IDBS is proud to announce that preclinical contract research organization (CRO) PharmaLegacy Laboratories (Shanghai, China) has selected the E-WorkBook Suite to increase its R&D productivity and deliver significant competitive advantage to clients.
Preclinical CRO selects E-WorkBook Suite to increase R&D productivity
Providing speciality pharmacology services in oncology, bone, inflammation and immune diseases, PharmaLegacy sought a 21 CFR Part 11 compliant solution for the capture of DMPK and pharmacology data to deliver improved customer service to clients. BioBook, the advanced biology extension of the E-WorkBook Suite, will be used by PharmaLegacy scientists in Shanghai as the company continues to expand and grow its customer base. BioBook will enable the company to significantly increase client productivity and the pace of new drug development by providing effective management and analysis of complex research data.
Tom Tillotson, Vice President Corporate Planning at PharmaLegacy, commented: “We have a vision to collaborate with our clients to accelerate their research missions to develop new therapies. The E-WorkBook Suite provides us with the highest level of IP protection and regulatory compliance and will enable us to offer improved discovery, development and management capabilities to the marketplace.” He added: “The benefits will be particularly great where client organizations are utilizing the BioBook technology. BioBook will provide us with an excellent opportunity to develop long-term partnerships with biotechnology and pharmaceutical clients.”
Neil Kipling, founder and CEO of IDBS, commented: “The need for new drug candidates has resulted in an increasingly important role for CROs. To remain competitive and increase the number of successful drug candidates for clients, CROs must employ effective data management solutions. BioBook provides focused preclinical data management extension to ensure maximum productivity and will help PharmaLegacy to deliver significant competitive advantage to clients in the pharmaceutical and biotechnology industries.”